Clinical trial · no report yet · Phase 3
PEARLS
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
- NCT02504372 ↗
- Completed
- Merck Sharp & Dohme LLC
- 101 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 40 | |
| Podcasts | 37 | |
| X threads | 24 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab; Placebo
- Arms
- Pembrolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 1,177
- Primary outcomes
- Disease-Free Survival (DFS)
- DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%
- Sponsor
- Merck Sharp & Dohme LLC with ETOP, European Organisation for Research and Treatment of Cancer - EORTC
- Start
- Nov 6, 2015
- Primary completion
- Jan 24, 2023
- Results posted
- Yes
- Registry record
- NCT02504372 · updated Mar 17, 2026
Publications
linked from the registry- O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12. PubMed 36108662